| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Castalagin — a high-molecular-weight C-glucosidic ellagitannin and dietary polyphenol found in camu camu (Myrciaria dubia), oak (Quercus spp.), chestnut (Castanea sativa), and several other plants. It is best classified with the chemical class ellagitannin / hydrolyzable tannin / polyphenol. No widely established pharmacological abbreviation exists; “castalagin” is preferable to creating an abbreviation. Its molecular formula is C41H26O26 and molecular mass is approximately 934.6 g/mol. Castalagin is the C-1 epimer of vescalagin and is converted by intestinal microbiota through intermediates including castalin and ellagic acid to urolithins. Its most compelling cancer activity is not conventional direct tumor-cell cytotoxicity but microbiome-dependent modulation of antitumor immunity and immune-checkpoint inhibitor response. Primary mechanisms (ranked):
Bioavailability / PK relevance: Intact castalagin appears to have very low systemic availability and functions predominantly within the gastrointestinal compartment. In mice receiving oral castalagin at doses up to approximately 17 mg/kg/day, intact castalagin was not detectable by HPLC in serum or feces, consistent with rapid transformation and strong interaction with the intestinal microbiota. Its biologically relevant systemic consequences therefore appear to arise mainly from microbiome restructuring and microbial metabolites, particularly urolithins and altered bile-acid profiles, rather than sustained circulating intact castalagin. Interindividual microbiome composition is consequently a major pharmacodynamic determinant. In-vitro vs systemic exposure relevance: Direct cellular effects observed with purified ellagitannins at micromolar concentrations should not automatically be interpreted as achievable systemic castalagin effects because intact oral castalagin has poor demonstrated systemic exposure. The strongest translationally relevant mechanism is gut-local and microbiome-mediated rather than concentration-driven exposure of tumors to intact castalagin. Importantly, ROS induction, DNA damage, and CHK1-inhibitor sensitization recently reported for castalin should not currently be assigned directly to castalagin. Clinical evidence status: Preclinical evidence for purified castalagin; early human adjunct evidence for castalagin-containing camu camu. Purified castalagin has demonstrated antitumor and anti-PD-1-resensitizing activity in multiple murine tumor models. Human oncology studies have administered camu camu rather than isolated pharmaceutical castalagin. A completed phase I study of camu camu plus immune-checkpoint therapy in melanoma and NSCLC reported acceptable safety and encouraging preliminary activity, with metabolomic changes including increased urolithins and altered bile acids. Two earlier ICI-refractory melanoma cases also showed durable responses after camu camu was added to nivolumab. A separate phase I renal-cell carcinoma study of camu camu with nivolumab/ipilimumab enrolled 31 patients but was listed as suspended in October 2026 for an administrative DSMC reporting issue after accrual had closed. Castalagin itself is therefore an experimental microbiome-directed immunotherapy adjunct and is not an approved anticancer drug. Castalagin Mechanistic Profile
|
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:529 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid